Citigroup Inc Kintara Therapeutics, Inc. Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$0.14 - $0.5 $70 - $250
-500 Closed
0 $0
Q1 2022

May 12, 2022
BUY
$0.31 - $0.55 $155 - $275
500 New
500 $0

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email